Author: Andrew Hoglund

Small Medical Companies Raising Big Funds
November 6, 2015
By Andrew Hoglund

Several companies in the medical field raised a fair amount of money this past week. Qvella raised $20 million to help develop and produce its pathogen analyzer that can identify infections in only 30 minutes. Conventus raised $21 million to help support its minimally invasive implants for fractures. Finally, CureVac has raised $110 million in an effort to create a therapeutic cancer vaccine. These funds should help provide a significant boost for each of these three companies. Qvella is close to creating a very powerful, very useful compact, inexpensive pathogen

Three Companies File IPOs To Help Further Their Business
September 1, 2015
By Andrew Hoglund

The Medical Device/Biotech field is constantly expanding, with new companies popping up every day. Once these companies get big enough, they generally will begin to consider going public with an IPO. A number of companies decided to file for an IPO last week, among them being Mirna, CytomX, and Acelity. These three companies are hoping that they can raise money through the IPO and then use that money to further produce/market their products. Mirna is filing to raise up to $80.5 million in order to advance its tumor suppressor MRX34

M&A deals headline the Medical Device/Pharma news this past week
July 28, 2015
By Andrew Hoglund

There have been several high profile merger and acquisition deals that took place this past week. St. Jude has decided to buy Thoratec for $3.4B, Allergan has acquired NMDA depression drugs in a $560M-plus Naurex buyout, and Teva has inked a $40B-plus pact for Allergan’s generics biz. M&A deals are the quickest way for a company to expand and grow in the market. St. Jude has announced its intention to acquire Thoratec for $3.4 billion, looking to incorporate its ventricular assist devices into St. Jude’s cardiology portfolio. St. Jude’s portfolio